Merlin@home Transmitter 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 St 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2017-01-10
  • 사례 출판 날짜
    2017-01-10
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: st. jude medical merlin@home transmitter the united states food and drug administration (fda) has issued a medical device safety alert concerning merlin@home transmitter, manufactured by st. jude medical. the fda is providing information and recommendations regarding st. jude medical's radio frequency (rf)-enabled implantable cardiac devices and merlin@home transmitter to reduce the risk of patient harm due to cybersecurity vulnerabilities. many medical devices—including st. jude medical's implantable cardiac devices—contain configurable embedded computer systems that can be vulnerable to cybersecurity intrusions and exploits. as medical devices become increasingly interconnected via the internet, hospital networks, other medical devices, and smartphones, there is an increased risk of exploitation of cybersecurity vulnerabilities, some of which could affect how a medical device operates. to improve patient safety, the manufacturer has developed and validated a software patch for the merlin@home transmitter that addresses and reduces the risk of specific cybersecurity vulnerabilities. the fda has reviewed st. jude medical's software patch to ensure that it addresses the greatest risks posed by these cybersecurity vulnerabilities, and reduces the risk of exploitation and subsequent patient harm. the fda conducted an assessment of the benefits and risks of using the merlin@home transmitter, and has determined that the health benefits to patients from continued use of the device outweigh the cybersecurity risks. the fda urges health care providers to: continue to conduct in-office follow-up, per normal routine, with patients who have an implantable cardiac device that is monitored using the merlin@home transmitter. remind patients to keep their merlin@home transmitter connected as this will ensure that patients' devices receive the necessary patches and updates. the fda urges patients and caregivers to: follow the labeling instructions provided with their merlin@home transmitter. keeping their monitor connected as directed will ensure their monitor receives necessary updates and patches. keep in mind that although all connected medical devices, including this one, carry certain risks, the fda has determined that the benefits to patients from continued use of the device outweigh the risks. seek immediate medical attention if they have symptoms of lightheadedness, dizziness, loss of consciousness, chest pain, or severe shortness of breath. for details, please refer to the fda websites: http://www.Fda.Gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm535979.Htm http://www.Fda.Gov/medicaldevices/safety/alertsandnotices/ucm535843.Htm if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 10 january 2017.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: St. Jude Medical Merlin@home Transmitter
  • Manufacturer
    St

Manufacturer

St
  • 제조사 모회사 (2017)
  • 제조사 의견
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DH